567 results on '"Joore Manuela A"'
Search Results
2. A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations
3. Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
4. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
5. Revising EU pharmaceutical legislation: will it foster drug repurposing?
6. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
7. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
8. The added value of risk assessment and subsequent targeted treatment for epileptic seizures after stroke: An early-HTA analysis
9. Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
10. Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
11. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
12. Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
13. Headroom Analysis for Early Economic Evaluation: A Systematic Review
14. The value of correctly diagnosing axial spondyloarthritis for patients and society
15. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
16. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer
17. Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
18. Bilateral vestibulopathy patients’ perspectives on vestibular implant treatment: a qualitative study
19. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
20. The effectiveness of health education interventions on cervical cancer prevention in Africa: A systematic review
21. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
22. Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer
23. Effectiveness of the Assessment of Burden of Chronic Conditions (ABCC)-tool in patients with asthma, COPD, type 2 diabetes mellitus, and heart failure: A pragmatic clustered quasi-experimental study in the Netherlands.
24. Quality of life in a real-world cohort of advanced breast cancer patients : a study of the SONABRE Registry
25. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
26. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
27. Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation
28. Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study
29. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
30. Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer
31. State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
32. BMI trajectories after primary school-based lifestyle intervention: Unravelling an uncertain future. A mixed methods study
33. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
34. Forecasting the value of innovation in total knee arthroplasty care: A headroom approach.
35. Identification and expert panel rating of key structural approaches applied in health economic obesity models
36. Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review
37. Navigating the Reimbursement Conundrum in Drug Repurposing: Balancing Access, Pricing, and Innovation
38. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
39. Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments
40. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
41. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
42. Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
43. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
44. Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
45. Whole genome sequencing in oncology: using scenario drafting to explore future developments
46. Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
47. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
48. The potential cost‐effectiveness of roflumilast drug treatment in mild cognitive impairment
49. Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
50. Response to Comment on “Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.